EC Medical Devices Vigilance System and Post Marketing Surveillance

This conference provides a unique opportunity to meet Competent Authorities, Notified Bodies, Lawyers, consultants and manufacturers to understand and discuss the regulatory and legal requirements with respect to Post Marketing Surveillance including Vigilance

28-29 Jan 2020

GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 20 Dec

Book now

Course Overview

Ensuring that a medical device remains safe and effective whilst on the market is an essential part of complying with the EU vigilance and post-marketing surveillance requirements outlined in the Directive 94/42/2 EC.

Competent authorities carry out market surveillance activities to certify that all devices comply with the latest regulations, ensuring that all devices in the market are safe for users. Post-marketing surveillance requires the manufacturer to monitor and review their devices to identify any need for corrective action. This activity is carried out in conjunction with authorised representatives, importers and distributors and is a key element of the manufacturer’s quality control system. It forms part of a PMS plan, which if carried out effectively can reduce the risk of adverse events. Manufacturers are then legally obliged, as part of a vigilance process, to report any serious incidents or correction measures to the relevant competent authorities.

Why you should attend

This seminar will give you practical advice on how to comply with the EU vigilance and post-market surveillance requirements. It will highlight manufacturers’ legal obligations and the risks associated with litigation, as well as providing essential guidance on how to report incidents in order to remain compliant. You will also gain practical advice and guidance on how to handle adverse event reporting during medical device clinical studies.

Attending these two days will offer you a unique opportunity to meet and network with Competent Authorities, Notified Bodies, lawyers, consultants and manufacturers to share good practice and experience.

Who should attend

This seminar will be of importance to all those involved in the medical device industry in the following roles and departments:

  • Regulatory affairs managers
  • Product safety managers
  • Post-market surveillance specialists
  • Global safety surveillance specialists
  • Vigilance managers
  • Pharmacovigilance co-ordinators
  • Pharmacovigilance associates
  • Report specialists
  • Manufacturing, registration, product safety, adverse event monitoring, regulatory affairs, distribution and all those interested in medical device vigilance in the European community

Programme day one

Chairmen’s Welcome and Introduction

Introduction to Post Marketing Surveillance
Tony Sant

In Depth Review of the EU Vigilance Process
Dr Ekkehard Stösslein


Application of the Reporting Rules
  • Case Studies
    Group Exercise led by Tony Sant and Dr Ekkehard Stösslein


Legal Aspects of Manufacturers Reporting Obligations
  • Main EU markets and US FDA
    Dr Grant Castle
Legal Aspects of FSCA
  • Product liability issues that might arise if one fails to take appropriate corrective action
  • The powers regulators have to act against products
    Dr Grant Castle


Field Safety Corrective Actions (FSCA): Expectations from Authorities
Dr Ekkehard Stösslein

Handling of Field Safety Corrective Actions (FSCA) – Industry Perspective
Janette Benaddi


Programme day two

Post Marketing Surveillance: an integral part of the QA system
  • Critical elements of risk Management, CAPA, PMS, Field Action SOPs
    Paul Sim

Role of Notified Bodies in vigilance
Paul Sim

Germany and vigilance:BfArM
  • Organisation
  • Handling of vigilance reports • National guidelines
  • Sharing of experiences
    Dr Ekkehard Stössleinn


UK and vigilance: MHRA
  • Organisation
  • Handling of vigilance reports • National guidelines
  • Sharing of experiences
    Tony Sant

Medical device regulation changes affecting PMS
Dr Ekkehard Stössleinn

Revision of vigilance guidelines:
  • Trending and FSN format
    Tony Sant

PMS and adverse event reporting during medical device studies
Janette Benaddi

Discussion and closing remarks

You may also be interested in

Adverse Event Management During Medical Device Clinical Studies on 28 January 2016


Janette Benaddi

Janette Benaddi is a business mentor, international speaker/trainer and consultant to the medical device industry. Janette has over 25 years’ experience of managing pre and post market clinical studies in both devices and pharmaceuticals. Janette has worked with several multinational organizations in various clinical, regulatory and marketing roles. She has extensive experience of conducting clinical studies with medical device products as well as regulatory expertise for CE marking of devices. Specifically she has been involved in writing and reviewing hundreds of Clinical evaluation reports for the medical device industry, she has also provided training to Notified bodies in this subject.

Janette qualified as a registered nurse in 1984, she has a BSc in Management studies, a Diploma in Company Direction, and a Diploma in Management studies, holds a teaching certificate and is a Chartered Scientist and Chartered Director. Janette sits on several committees in the device community and industry and has been an instrumental advocate of improving and advancing medical device research in the UK. Janette has published several articles relating to medical device regulation and clinical studies.

Ekkehard Stosslein

Dr. Ekkehard Stösslein is a Senior Expert for Vigilance, Germany. He has many years experience in medical device regulations, particularly vigilance systems and post marketing surveillance in a leading position with a federal competent authority in Germany. He is an active member of the Medical Devices Coordination Group on Vigilance and was a member of the Study Group II of the Global Harmonisation Task Force.

Grant Castle

Grant Castle is a Partner in the London office of Covington & Burling, practicing in food and drug regulatory law, with an emphasis on pharmaceutical and medical device regulation and associated data protection laws.
He has assisted clients with applications for the centralised approval of medicinal products, EC orphan drug designation, and with regulatory issues in the national approval process for medicines, including the EC mutual recognition procedure. He has participated in formal and informal good manufacturing practices (GMP), good clinical practices (GCP), advertising, borderline, drug safety and pharmacovigilance proceedings before the European Medicines Agency (EMEA), national authorities, courts and self-regulatory bodies. His litigation experience includes judicial review proceedings in the UK and EC courts, including the first challenge to a Community marketing authorisation for a medicinal product in the European Court of First Instance.
He received a BSc in Chemistry with first class honours from Imperial College of Science, Technology and Medicine in London in 1991 and a PhD in Organic Chemistry from Trinity College, University of Cambridge in 1994.
He has published extensively in the legal literature and has made several contributions to the technical literature in chemistry. He speaks and lectures frequently on pharmaceutical, medical device, data privacy and borderline products regulation at the Universities of Surrey and Wales, University of Cranfield, and business and professional groups in Europe and the U.S.

Paul Sim

Paul Sim, Regulatory Affairs Manager, BSi Group. Paul has worked in the healthcare industry for 34 years and is currently Project Managing BSI’s implementation of EU Commission Recommendation 2013/473/EU dealing with Unannounced Audits. Joining BSI in August 2010 leading the BSI effort working with the Saudi Food & Drug Authority on the implementation of the SFDA Medical Device Interim Regulations.

Previously he held senior RAQA leadership positions at Spacelabs Healthcare, Teleflex Medical, Smiths Medical, Ohmeda (formerly The BOC Group healthcare business)

Medical Device experience is across a very broad range of devices including: anaesthesia systems, patient monitors, vapourisers, ventilators, breathing circuits, single use sterile disposables and devices for re-use, infant warmers, incubators, steralisers, autoclaves, operating tables, infusion pumps and associated disposables, urinary catheters, surgical instruments, diagnostic cardiology etc.

Paul is a member of the Association of British Healthcare Industries (ABHI) Technical Policy Group and is Convenor of the ABHI ISO TC 210 Mirror Group. Convenor of the BSI Committee, which monitors all of the work undertaken by ISO TC 210, and Convenor of the BSI Sub-committee dealing with Quality Systems. As UK Delegation Leader to ISO TC 210, Paul is also actively involved in the work of national, European and international standards’ committees, dealing with revisions to the ISO 9000 series, ISO 13485, ISO 14971, ISO 15223 and others. He is Deputy Chairman and Council Member of Barema (British Anaesthetic & Respiratory Manufacturers Association), also a Member of the Association of Anaesthetists of Great Britain and Ireland (AAGBI) Safety Committee.

Tony Sant

Tony Sant is a Group Manager for MHRA’s Adverse Incident Centre and Biosciences and Implants specialist unit. He graduated in Physics at Imperial College, London and went on to obtain an MSc in Medical Physics and Medical Electronics at St Bartholomew’s Hospital. He joined one of MHRA’s precursors in 1985 from Medeci Medical Ltd. where he was employed as a medical electronics test engineer. At MHRA he has gained experience in: adverse incident investigation and incident systems development, quality systems auditing; medical device research and development, medical device evaluation project management, and general management of staff and other resources.
He has been instrumental in MHRA introducing and developing on-line reporting for users and manufacturers and was also closely involved in the development of SABRE MHRA’s Haemovigilance reporting system in 2005. He has been an active European representative of Study Group 2 (Adverse Events and Postmarket Surveillance) of the Global Harmonisation Task Force, where he led on guidance documents for electronic reporting of adverse incidents. He is an active member of the European Medical Device Experts Group on Vigilance and its sub-groups which recently revised the EU’s vigilance guidance and which currently are developing proposals for future comitology and recasting of EU medical device vigilance.

Book now

28-29 Jan 2020
28-29 Jan 2020 Cavendish Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 20 Dec*
Enrol now

* Note the early booking discount cannot be combined with any other offers or promotional code

You may also be interested in

Previous customers include...

  • Aerocrine AB
  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Allergan UK Limited
  • Arnold & Porter
  • Baxter R&D Europe
  • BD Saudi Arabia Office
  • bioMerieux SA
  • Biomet UK Ltd
  • Boston Scientific
  • Contura International A/S
  • ConvaTec UK Ltd
  • Covidien (UK) Commerical Limited
  • Dada Consultancy BV
  • Depuy CMW
  • Korea Health Industry Development Institute (KHIDI)
  • Neurodan A/S
  • Novo Nordisk Ltd
  • Oxoid Thermo Fisher Scientific Ltd
  • PA Consulting
  • Perrigo
  • PharSafer Associates Ltd
  • Sinclair Pharma SRL
  • Thermo Fisher Scientific Oy
  • Valtech Cardio Ltd
  • W.L. Gore and Associates

Excellent course, definitely recommended!

Lushendrie Naidoo, Quality Concerns Coordinator , Olympus KeyMed

Great job over all. Highly skilled speakers and highly relevant content.

Søren Møller Madsen, RA specialist, Radiometer Medical ApS

I thought it was a very informative and comprehensive course given by knowledgeable speakers.

Gerrie ONeill, Snr Reg Affairs Specialislt, Boston Scientific

Course ran at a good pace to allow digestion of the information being presented. Good speakers who are obviously well educated in their subject matter.

Jon Brightwell, Quality Concerns Coordinator, Olympus KeyMed

Good breadth and depth of content. Too much unrelenting power point. The speakers were generally very good.

Kevin Buchanan, Senior Customer Quality Engineer, LifeScan

Very good overall.

Claire Lacey, Regulatory Affairs Asssociate, Olympus Keymed

Very useful information provided by well qualified speakers.

Alison Etchells, Regulatory Affairs Officer, Thornton & Ross Ltd

Overall it was good. Good level of detail.

Vikash Sarpal, Pharmacovigilance Associate, PharSafer

Good selection of speakers from very broad backgrounds. Particularly useful to have speakers from UK authorities.

Suna Horner, Associate Medical Manager, HRA Pharma UK & IE Ltd.

Overall the content was good

Claudio Colasante, Medical Events Specialist, Johnson and Johnson Vision

Interesting and good topics.

Bolette Duun-Christensen, RA Specialist , Radiometer Medical ApS

Overall, really very good

Ben Rees, PV Team Lead, PharSafer Associates Ltd

Professional, content perfect for attendees. Speakers were engaging and put a human face on the CA's and RB's.

Judy Grealish, Coronary PXM Engineering Supervisor, Medtronic

Well structured with good experience represented

Katrine Dester, QA/RA coordinator, Contura International A/S

Just the right content and duration.

John Hart, Head of Global Pharmacovigilance & EU QPPV, Besins Healthcare

Well worth attending. I had a very enjoyable time and would be interested in different courses ran by yourself. It was interesting to have different perspectives on Vigilance and PMS.

Bryony Catt, Vigilance Specialist, Sinclair Pharmaceuticals Ltd

Very interesting training

Sonia Pinel, IBA

Each speaker is competent and open-minded for discussion. Lot of examples to help understanding. Open discussion

Maud Andriollo-Sanchez, Vigilance manager, TORNIER SAS - Wright Cie